Cantabio Pharmaceuticals Inc. (CTBO) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2225 EAST BAYSHORE ROAD PALO ALTO, CA 94303 |
| State of Incorp. | DE |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2018 | 3/31/2017 | 3/31/2016 | 3/31/2015 | 3/31/2014 | 3/31/2013 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 32,275 | 52,110 | 4,567 | 16,654 | ||||
| Cash and cash equivalents | 32,275 | 52,110 | 4,567 | 16,654 | ||||
| Prepaid expense | 1,248 | ✕ | ||||||
| Prepaid expense and other current assets | ✕ | ✕ | ✕ | ✕ | ✕ | 12,500 | ||
| Total current assets: | 33,523 | 52,110 | 4,567 | 29,154 | ||||
| Noncurrent Assets | ||||||||
| Other undisclosed assets | 1,000 | |||||||
| TOTAL ASSETS: | 33,523 | 52,110 | 4,567 | 30,154 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 377,893 | 225,498 | 18,584 | 6,633 | 14,300 | |||
| Accrued liabilities | 140,142 | 173,414 | 18,584 | 6,633 | 14,300 | |||
| Other undisclosed accounts payable and accrued liabilities | 237,751 | 52,084 | ||||||
| Debt | 322,256 | |||||||
| Due to related parties | 47,154 | 22,982 | 8,804 | 1,387 | ||||
| Other undisclosed current liabilities | 140,142 | 173,414 | ||||||
| Total current liabilities: | 887,445 | 421,894 | 27,388 | 6,633 | 15,687 | |||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 887,445 | 421,894 | 27,388 | 6,633 | 15,687 | |||
| Equity | ||||||||
| Equity, attributable to parent | (853,922) | (369,784) | (27,388) | (2,066) | 14,467 | |||
| Common stock | 26,805 | 26,805 | 4,850 | 4,850 | 3,650 | |||
| Common stock, value, subscriptions | 1,060,000 | 500,000 | ✕ | ✕ | ||||
| Additional paid in capital | 167,324 | 99,324 | 113,467 | 113,467 | 44,350 | |||
| Accumulated deficit | (2,108,051) | (995,913) | (145,705) | (120,383) | (33,533) | |||
| Total equity: | (853,922) | (369,784) | (27,388) | (2,066) | 14,467 | |||
| TOTAL LIABILITIES AND EQUITY: | 33,523 | 52,110 | 4,567 | 30,154 | ||||
Income Statement (P&L) (USD)
| 3/31/2018 | 3/31/2017 | 3/31/2016 | 3/31/2015 | 3/31/2014 | 3/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Gross profit: | (32,000) | ||||||
| Operating expenses | (1,788,228) | (1,532,715) | (25,322) | (86,850) | (26,582) | ||
| Other undisclosed operating income | 16,132 | 3,828 | |||||
| Operating loss: | (1,788,228) | (1,564,715) | (25,322) | (86,850) | (26,582) | ||
| Nonoperating income (expense) | 25,131 | (18,267) | |||||
| Loss, foreign currency transaction, before tax | (18,275) | ||||||
| Debt instrument, convertible, beneficial conversion feature | 68,000 | ||||||
| Other nonoperating income (expense) | (42,869) | 8 | |||||
| Interest and debt expense | (39,869) | 107,884 | |||||
| Loss from continuing operations before income taxes: | (1,802,966) | (1,475,098) | (25,322) | (86,850) | (26,582) | ||
| Income tax expense (benefit) | (9,038) | ||||||
| Loss from continuing operations: | (1,802,966) | (1,475,098) | (25,322) | (86,850) | (35,620) | ||
| Loss before gain (loss) on sale of properties: | (1,802,966) | (1,475,098) | (25,322) | (86,850) | (35,620) | ||
| Net loss: | (1,802,966) | (1,475,098) | (25,322) | (86,850) | (35,620) | ||
| Other undisclosed net income attributable to parent | 690,828 | 723,770 | 9,038 | ||||
| Net loss available to common stockholders, diluted: | (1,112,138) | (751,328) | (25,322) | (86,850) | (26,582) | ||
Comprehensive Income (USD)
| 3/31/2018 | 3/31/2017 | 3/31/2016 | 3/31/2015 | 3/31/2014 | 3/31/2013 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (1,802,966) | (1,475,098) | (25,322) | (86,850) | (35,620) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,802,966) | (1,475,098) | (25,322) | (86,850) | (35,620) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.